ASCO Shares Cancer Funding Priorities for FY25

Association urges Congress to provide robust funding to NIH, NCI, other agencies
May 21, 2024

The Association for Clinical Oncology (ASCO) is urging lawmakers to continue their bipartisan support for federal cancer research in Fiscal Year (FY) 2025. This funding is vital for the National Institutes of Health (NIH), National Cancer Institute (NCI) and other agencies in their work to advance science.

For FY 2025, ASCO is asking Congress to provide $51.303 billion for the NIH, $7.934 billion for the NCI, $1.5 billion for the Advanced Research Projects Agency for Health, and $472.5 million for the CDC’s Division of Cancer Prevention and Control.

ASCO has shared its formal funding requests for FY25 with the House and Senate Committees on Appropriations, Subcommittee on Labor, Health and Human Services, Education and Related Agencies. In written testimony submitted earlier this month, ASCO Board Chair Everett E. Vokes, MD, FASCO, urged lawmakers to make cancer research a priority,

He emphasized that a “strong commitment to scientific discovery” can speed the development of innovative treatments and sustain the nation’s position as the world leader in biomedical research. He noted that in 2023, NIH provided $37.81 billion in research funding to scientists in all 50 states and the District of Columbia, which supported over 412,000 jobs and generated $92.89 billion in economic activity.

“It is imperative that NIH maintains the capacity to support fundamental science across all scientific disciplines to replicate and build upon these successes and ultimately realize the cures they promise,” Dr. Vokes wrote.

As the largest funder of cancer research globally, NCI’s R01 grant applications have increased almost three times than the rest of the NIH combined, yet the agency’s funding has failed to keep pace, Dr. Vokes said.

“We strongly urge Congress to maintain the momentum of the Cancer Moonshot by fully supporting and funding the goals and strategies in the National Cancer Plan,” he wrote. “With your unwavering support, the NCI can realize the ambitious Moonshot goals of ending cancer as we know it today, significantly reducing the cancer death rate, and improving the experience of the people living with and surviving cancer, their families, and caregivers.”

ASCO additionally submitted testimony to the House and Senate Subcommittees on Agriculture, Rural Development, Food and Drug Administration, and Related Agencies requesting $3.896 billion for the FDA to support the agency’s work on drug shortages, tobacco prevention and control, and other priority areas. 

"It is important Congress ensures transparency into the entire [pharmaceutical] supply chain, by requiring manufacturers to report more actionable information to the FDA, in a useable format, to give the agency an earlier and more holistic picture of the actual and anticipated supply of any given drug," Dr. Vokes wrote. 

Join ASCO and urge your lawmakers to support cancer research. To send a letter directly to your members of Congress, visit the ACT Network.

Bookmark ASCO in Action for updates as well as news, advocacy, and analysis on cancer policy.